CD274 and neoplasm: PD‐L1 was reported to be a marker of NK‐cell activation, and NK cells expressing PD‐L1 showed enhanced antitumour activity, which could be further activated by atezolizumab against PD‐L1‐ tumours independent of PD‐1.14